| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2530740 | Current Opinion in Pharmacology | 2006 | 5 Pages |
Abstract
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Elizabeth Ruth Plummer,